The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Study 0099 explores the efficacy and safety of multiple doses of velusetrag in the treatment
of symptoms in subjects with diabetic or idiopathic gastroparesis. Three dose levels of
velusetrag will be evaluated and compared to placebo for approximately 12 weeks of therapy.
In addition, the study will be used to evaluate the psychometric properties of the
Gastroparesis Rating Scale (GRS), a daily patient-reported outcome (PRO) measure.
Phase:
Phase 2
Details
Lead Sponsor:
Theravance Biopharma Theravance Biopharma R & D, Inc.